The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation

Anticoagulant therapy of patients with atrial fibrillation is an integral part of their treatment strategy. The high risk of developing a cardioembolic stroke and the high comorbidity of this group of patients necessitates a comprehensive approach to treatment, taking into account all available risk...

ver descrição completa

Detalhes bibliográficos
Principais autores:	I. A. Zolotovskaya, V. D. Sabanova, I. L. Davydkin
Formato:	Artigo
Idioma:	English
Publicado em:	Столичная издательская компания 2021-05-01
coleção:	Рациональная фармакотерапия в кардиологии
Acesso em linha:	https://www.rpcardio.online/jour/article/view/2411

Registros relacionados

Marfanoid appearance as a risk factor for atrial fibrillation in patients with osteoporosis
por: I. A. Zolotovskaya, et al.
Publicado em: (2016-06-01)

THE OPPORTUNITIES FOR RISK REDUCTION OF RECURRENT STROKE IN ATRIAL FIBRILLATION
por: I. L. Davydkin, et al.
Publicado em: (2015-06-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
por: I. Yu. Koroleva, et al.
Publicado em: (2016-11-01)

ANTICOAGULATION IN ATRIAL FIBRILLATION PATIENTS AFTER CARDIOEMBOLIC STROKE: EVALUATION OF TREATMENT ADHERENCE IN REAL PRACTICE (Cohort study “APOLLON”)
por: I. A. Zolotovskaya, et al.
Publicado em: (2017-08-01)

Atrial fibrillation in elderly patients. Features of using rivaroxaban
por: A. D. Erlikh
Publicado em: (2020-06-01)

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
por: Chan, Kevin E., et al.
Publicado em: (2016)

NEWLY DIAGNOSED STROKE-ASSOCIATED ATRIAL FIBRILLATION: RISK OF DEVELOPMENT OF UNFAVORABLE CLINICAL OUTCOMES (THE RESULTS OF THE SUBANALYSIS COHORT STUDY APOLLO)
por: I. A. Zolotovskaya, et al.
Publicado em: (2017-09-01)

Predictive markers of atrial fibrillation in patients after acute ST-elevated myocardial infarction (the results of observational program “FAKEL”)
por: I. A. Zolotovskaya, et al.
Publicado em: (2018-10-01)

Cardiorenal relationships in the focus of risks of atrial fibrillation in patients after acute ST-elevated myocardial infarction (observational program FAKEL)
por: I. A. Zolotovskaya, et al.
Publicado em: (2019-05-01)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
por: N. A. Shatalova, et al.
Publicado em: (2023-11-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
por: M. Yu. Gilyarov
Publicado em: (2015-12-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
por: M. Yu. Gilyarov
Publicado em: (2015-12-01)

Potential for anticoagulant therapy in the most vulnerable groups of patients
por: Irina A. Zolotovskaya, et al.
Publicado em: (2022-02-01)

IMPACT OF ANTICOAGULANT THERAPY ON THE INDICATORS OF ARTERIAL STIFFNESS AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CARDIOEMBOLIC STROKE
por: I. A. Zolotovskaya, et al.
Publicado em: (2016-12-01)

FUNCTIONAL STATE OF THE MICROCIRCULATION OF THE SKIN ACCORDING TO LASER DOPPLER FLOWMETRY IN PATIENTS WITH ATRIAL FIBRILLATION WHO UNDERWENT CARDIOEMBOLIC STROKE
por: I. A. Zolotovskaya, et al.
Publicado em: (2017-12-01)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
por: S. V. Nedogoda, et al.
Publicado em: (2017-03-01)

ATRIAL FIBRILLATION COMBINED WITH DIABETES MELLITUS. POSSIBILITIES OF USING RIVAROXABAN
por: Alexey D. Ehrlich
Publicado em: (2018-12-01)

Biological Variation in Rotational Thromboelastometry in Patients with Atrial Fibrillation Receiving Rivaroxaban
por: Mojca Božič Mijovski, et al.
Publicado em: (2022-06-01)

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban
por: Francisco Marin, et al.
Publicado em: (2023-02-01)

Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita
por: S. N. Bel'diev
Publicado em: (2016-03-01)

Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation
por: Mindi Zhao, et al.
Publicado em: (2022-08-01)

Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation
por: Yang-Qi Pan, et al.
Publicado em: (2024-02-01)

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation
por: article Editorial
Publicado em: (2022-03-01)

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation
por: Huamin Ding, et al.
Publicado em: (2024-07-01)

Efficacy and safety of rivaroxaban in prevention and therapy of thromboembolic events in patients with nonvalvular atrial fibrillation
por: Tamara Kovačević Preradovic, et al.
Publicado em: (2023-01-01)

Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin
por: Monirah Abdulrahman Albabtain, et al.
Publicado em: (2023-01-01)

Suspected Hematuria: Adverse Effects of Rivaroxaban in Older Adult Treated for Atrial Fibrillation
por: Aleksandra Rapaić, et al.
Publicado em: (2024-02-01)

Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban
por: Liselotte Onelöv, et al.
Publicado em: (2024-03-01)

Prothrombin Time-International Normalized Ratio Predicts the Outcome of Atrial Fibrillation Patients Taking Rivaroxaban
por: Tze-Fan Chao, et al.
Publicado em: (2022-12-01)

THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING
por: N. A. Novikova, et al.
Publicado em: (2017-05-01)

An Integrated Approach to the Management of a Multimorbid Patient with Atrial Fibrillation from the Standpoint of Modern Guidelines: Rivaroxaban is in Focus
por: V. N. Larina, et al.
Publicado em: (2021-07-01)

Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation
por: Chen G, et al.
Publicado em: (2024-05-01)

Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation
por: S. G. Kanorskii
Publicado em: (2016-09-01)

The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke
por: Neda Jaberi, et al.
Publicado em: (2021-01-01)

Nomogram for predicting bleeding events in nonvalvular atrial fibrillation patients receiving rivaroxaban: A retrospective study
por: Chang Cao, et al.
Publicado em: (2024-01-01)

Inhibitory effect of rivaroxaban on protease-activated receptor-2 in circulating neutrophils among patients with atrial fibrillation
por: Makoto Nakano, et al.
Publicado em: (2024-06-01)

ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION
por: O. A. Zemlyanskaya, et al.
Publicado em: (2019-06-01)

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN
por: I. S. Yavelov
Publicado em: (2016-07-01)

POSSIBILITIES OF PHARMACOLOGICAL CORRECTION OF STRUCTURAL AND FUNCTIONAL ALTERATIONS OF MICROCIRCULATION IN TERMS OF ENDOTHELIAL DYSFUNCTION IN COMORBID PATIENTS SUFFERED STROKE EVENT
por: I. A. Zolotovskaya, et al.
Publicado em: (2016-09-01)

The main clinical and diagnostic characteristics of patients with low back pain and sacroiliac joint diseases (results of the IOLANTA-II study)
por: I. A. Zolotovskaya, et al.
Publicado em: (2020-08-01)